Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?
# Background The Inflation Reduction Act’s Medicare Drug Price Negotiation Program allows the federal government to negotiate caps for select medications. These price caps may reduce revenue for the pharmacy benefit managers (PBMs) that negotiate the actual price paid for medicines in the U.S. To of...
Saved in:
| Main Authors: | Anne M. Sydor, Esteban Rivera, Robert Popovian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-11-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.125251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?
by: Anne M. Sydor, et al.
Published: (2024-03-01) -
Does inflation uncertainty hurt domestic investment? Empirical evidence from Ghana
by: Kofi Kamasa, et al.
Published: (2022-12-01) -
The Beholder’s Hurt Feeling
by: Claudia Keller
Published: (2012-04-01) -
Oil price passthrough to consumer price inflation in South Africa: the role of the inflation environment
by: Eliphas Ndou, et al.
Published: (2025-12-01) -
DOES “HURT” HELP? A Review of Miriam Boeri’s HURT: Chronicles of the Drug War Generation
by: George K. Danns Dr.
Published: (2019-10-01)